Phase II trial of serplulimab combined with gemcitabine plus nab-paclitaxel (GnP) and SBRT for metastatic pancreatic cancer as the first-line treatment.

作者
Ke Cheng,Chenyan Zhang,Gang Zhao,Xiaoying Li,Jiaxin Liu,Zhiping Li,Heqi Yang,Bole Tian,Chengjian Zhao,Dan Cao
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 4160-4160 被引量:4
标识
DOI:10.1200/jco.2025.43.16_suppl.4160
摘要

4160 Background: The addition of anti-PD-1 monoclonal antibody (mAb) to gemcitabine and nab-paclitaxel (GnP) presented limited improvement in objective response rate (ORR) and disease control rate (DCR) for metastatic pancreatic ductal adenocarcinoma (mPDAC) in our previous study. Therefore, we conducted this phase II trial to evaluate the efficacy and safety of anti-PD-1 mAb (Serplulimab) plus GnP chemotherapy and stereotactic body radiotherapy (SBRT) in patients with mPDAC. Methods: Patients with mPDAC without previous treatment were enrolled to receive Serplulimab and GnP plus SBRT (SGSBRT) (intravenous infusion of Serplulimab 200 mg on day 1 every 3 weeks, gemcitabine 1000 mg/m 2 and nab-paclitaxel 125 mg/m 2 on day 1 and day 8, repeated every 3 weeks; SBRT delivered 5 fractions of 6.6 Gy to the primary tumor or 3 fractions of 8 Gy to the metastatic lesion in cycle 2) as the first-line treatment. The primary endpoint was 6-month progression-free survival (PFS) rate. Secondary endpoints included overall survival (OS), PFS, ORR, DCR, and adverse events (AEs). Moreover, the biomarkers such as circulating tumor DNA (ctDNA) and circulating hybrid cells (CHCs), PD-L1 expression, tumor tissue genetic status, cytokine levels, and immune microenvironment were also investigated. Results: As of January 2025, 47 patients have been enrolled and 41 patients have been followed for more than 6 months, with all 47 patients achieving efficacy according to the protocol. The 6-month PFS rate was 78.48%. The ORR was 74.47% (35/47), including 1 complete response (CR) and 34 partial responses (PR), and the DCR was 100%, with 12 stable disease (SD). The median PFS was 8.6 months, and the median OS was 15.5 months. The frequent grade 3 drug-related AEs were neutropenia (20/47, 42.55%), leukopenia (19/47, 40.43%), anorexia (18/47, 38.30%), and fatigue (11/34, 23.40%). The correlation between biomarkers and efficacy and prognosis are under-analyzed. Conclusions: This phase II study has met our preset primary endpoint with 78.48% in 6-month PFS rate, and SGSBRT presented promising efficacy with manageable safety profile and expected antitumor activity. This combination might be a promising option as first-line therapy for Chinese patients with mPDAC. Clinical trial information: ChiCTR2300073237 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Lxry发布了新的文献求助10
1秒前
1秒前
zzhc发布了新的文献求助10
1秒前
爆米花的应助被澹青云采纳,获得10
1秒前
2秒前
ccccelia完成签到,获得积分10
2秒前
mingxuan完成签到,获得积分10
2秒前
小马甲的应助被xiuuu采纳,获得10
2秒前
等你下课发布了新的文献求助10
2秒前
顾矜的应助被FeCl采纳,获得10
3秒前
JamesPei的应助被顺利的莺采纳,获得10
3秒前
3秒前
水煮电吹风的应助被wyh采纳,获得10
3秒前
Orange的应助被youyyuy采纳,获得10
3秒前
毫无意义完成签到,获得积分10
3秒前
水煮电吹风的应助被唐飒采纳,获得10
4秒前
水煮电吹风的应助被唐飒采纳,获得10
4秒前
Nole的应助被zzZ5采纳,获得30
4秒前
英姑的应助被调皮钧采纳,获得10
5秒前
肖馨余发布了新的文献求助30
5秒前
huhuiya发布了新的文献求助10
5秒前
歪比巴布完成签到,获得积分10
6秒前
6秒前
xx发布了新的文献求助10
6秒前
科研通AI6.2的应助被静水流深采纳,获得10
6秒前
酷波er的应助被杨子墨采纳,获得10
6秒前
6秒前
小宇biu完成签到,获得积分10
7秒前
Auba完成签到,获得积分10
7秒前
7秒前
丘比特的应助被邓少军采纳,获得10
7秒前
CarryLJR的应助被萌萌采纳,获得10
7秒前
7秒前
羊翊婕发布了新的文献求助10
8秒前
8秒前
我是老大的应助被wzy采纳,获得10
8秒前
9秒前
Nuyoah发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287